Leeds commission UK’s largest digital health service

An app developed by a Yorkshire tech company is set to ease the burden on the NHS and improve lives for thousands of people across Leeds, experiencing daily chronic pain.

The new service covers the population of the city of Leeds, and is initially available to over 7,000 patients, making it the largest digital health service to be commissioned in the UK.

The downloadable app which is completely free for patients to use, gives them the knowledge, skills and guidance to manage their pain, which should reduce the need to visit their GP or hospital.

Painsense has been created by Saltaire-based ADI (Advanced Digital Institute), with support from the NHS England SBRI programme. It is currently being used within the healthcare sector in the Leeds and West Yorkshire area and will be rolled out across other regions of the UK within the next six months.

Digital health specialists Inhealthcare, a Harrogate-based firm have played an instrumental part in fully integrating the app into the pain management pathway and GP systems so patient data can be transferred safely and securely. This means it can also be easily accessed before and during consultations.

Dr Jamie O’Shea of Leeds West NHS CCG, pictured second right, said: “The Pain Toolkit app has recently been introduced in Leeds to encourage supported self-management of persistent pain. I have introduced this app to several patients who have unanimously provided extremely positive feedback and I am very confident we will see improved outcomes for this cohort of individuals.”

Huw Jones of ADI, seen second left, added: “The app has been developed with patients and healthcare professionals over a 2 year period. So far the reaction has been extremely positive.”

“It could revolutionise the doctor patient relationship for the estimated 8 million people in the UK suffering with pain. The app includes two related elements in the form of the established Pain Toolkit, which contains a wealth of information and assessment tools, and the Pain Management Plan that helps the patient structure a plan to manage their experience of pain.”

Bryn Sage, CEO of Inhealthcare said: “A key ambition of NHS England has been to enable every patient to be able to submit health related data directly into their health records. Leeds is the first city in the UK to adopt, across every GP surgery, infrastructure that allows every patient to send information back to their GP electronically.

“This type of digital health service is just what the Government and NHS England are crying out for. The NHS needs to meet cost savings of over £22 billion this year, and driving efficiency through technology will play a huge part in clawing back on that deficit.

“As Leeds has shown, by adopting universally a digital health platform that supports a range of health innovations, you can increase the effectiveness of treatment, use resources more efficiently and get greater engagement with the public.

This work was commissioned and funded by the SBRI Healthcare programme. SBRI Healthcare is an NHS England initiative, championed by the Academic Health Science Networks (AHSNs).


A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Brilinta approved in US to reduce the risk of first heart attack or stroke

AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with...

GSK to manufacture 1bn doses of pandemic vaccine

GlaxoSmithKline (GSK) is aiming to manufacture one billion doses of its pandemic vaccine adjuvant system, in 2021, to support the development of multiple adjuvanted...

Chimeron Bio & NCBID to develop COVID-19 vaccine

RNA therapeutics company, Chimeron Bio, and George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID), will together develop a COVID-19 vaccine. The vaccine...

AbCellera raises $105m to advance antibody drug discovery platform

AbCellera has closed a $105 million Series B financing to further advance its antibody drug discovery platform. The financing was led by OrbiMed and current...

Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha...

Related news

Emergent joins partnership for COVID-19 vaccine development & manufacturing

Emergent BioSolutions has been issued a task order under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA) to deploy its...

Brilinta approved in US to reduce the risk of first heart attack or stroke

AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with...

GSK to manufacture 1bn doses of pandemic vaccine

GlaxoSmithKline (GSK) is aiming to manufacture one billion doses of its pandemic vaccine adjuvant system, in 2021, to support the development of multiple adjuvanted...

Chimeron Bio & NCBID to develop COVID-19 vaccine

RNA therapeutics company, Chimeron Bio, and George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID), will together develop a COVID-19 vaccine. The vaccine...